Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.06%
median of 809 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Enliven Therapeutics, Inc.
Market Cap
$2.99B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.01B
Net Profit Margin
6.15%
TTM Avg
-37.77%
3Y Avg
-2241.27%
5Y Avg
-1494.18%
Market Cap
$3.07B
Net Profit Margin
0.00%
TTM Avg
-172.68%
3Y Avg
-306.20%
5Y Avg
-1288.24%
Market Cap
$3.08B
Net Profit Margin
-14191.20%
TTM Avg
0.00%
3Y Avg
-86.13%
5Y Avg
-153.41%
Market Cap
$2.82B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.81B
Net Profit Margin
22.69%
TTM Avg
19.73%
3Y Avg
-2.42%
5Y Avg
-44.65%
Market Cap
$3.19B
Net Profit Margin
-7.67%
TTM Avg
-38.94%
3Y Avg
-274.32%
5Y Avg
-186.92%
Market Cap
$2.79B
Net Profit Margin
1.85%
TTM Avg
-5.88%
3Y Avg
-8.36%
5Y Avg
-6.41%
Market Cap
$2.71B
Net Profit Margin
-183.98%
TTM Avg
-2902.19%
3Y Avg
-1809.95%
5Y Avg
-1403.14%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $2.99B | 0.00% | 0.00% | 0.00% | 0.00% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.01B | 6.15% | -37.77% | -2241.27% | -1494.18% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.07B | 0.00% | -172.68% | -306.20% | -1288.24% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.08B | -14191.20% | 0.00% | -86.13% | -153.41% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.82B | 0.00% | 0.00% | 0.00% | 0.00% |
| TransMedics Group, Inc. (TMDX)vs › | $2.81B | 22.69% | 19.73% | -2.42% | -44.65% |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | -7.67% | -38.94% | -274.32% | -186.92% |
| AtriCure, Inc. (ATRC)vs › | $2.79B | 1.85% | -5.88% | -8.36% | -6.41% |
| Precigen, Inc. (PGEN)vs › | $2.71B | -183.98% | -2902.19% | -1809.95% | -1403.14% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.30B | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
